Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Clearmind Medicine (Nasdaq: CMND) announced the publication of a European patent application for its combination therapy using MEAI and N-Acylethanolamines. The therapy targets various binge behaviors, including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent stems from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on combining psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA). The company has filed 13 patents across multiple jurisdictions related to this collaboration, strengthening its intellectual property portfolio in psychedelic therapies for binge behavior treatment.
Clearmind Medicine (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto europeo per la sua terapia combinata che utilizza MEAI e N-Acilethanolamine. La terapia è mirata a vari comportamenti di binge, tra cui alcol, alimentazione, tabacco, shopping e condotta sessuale.
Il brevetto deriva dalla collaborazione di Clearmind con SciSparc (Nasdaq: SPRC), focalizzandosi sulla combinazione di composti psichedelici con la famiglia delle N-Acilethanolamine, inclusa la Palmitoiletanolammina (PEA). L'azienda ha presentato 13 brevetti in diverse giurisdizioni relativi a questa collaborazione, rafforzando il proprio portafoglio di proprietà intellettuale nelle terapie psichedeliche per il trattamento dei comportamenti di binge.
Clearmind Medicine (Nasdaq: CMND) anunció la publicación de una solicitud de patente europea para su terapia combinada que utiliza MEAI y N-Acilethanolaminas. La terapia se dirige a varios comportamientos de atracón, incluyendo el alcohol, la alimentación, el tabaco, las compras y la conducta sexual.
La patente proviene de la colaboración de Clearmind con SciSparc (Nasdaq: SPRC), centrándose en combinar compuestos psicodélicos con la familia de las N-Acilethanolaminas, incluida la Palmitoiletanolamina (PEA). La empresa ha presentado 13 patentes en múltiples jurisdicciones relacionadas con esta colaboración, fortaleciendo su cartera de propiedad intelectual en terapias psicodélicas para el tratamiento de comportamientos de atracón.
클리어마인드 메디슨 (Nasdaq: CMND)은 MEAI와 N-아실에탄올아민을 활용한 복합 요법에 대한 유럽 특허 출원 발표를 알렸습니다. 이 요법은 알코올, 음식, 담배, 쇼핑, 성행위를 포함한 다양한 폭식 행동을 목표로 합니다.
이 특허는 클리어마인드와 사이사파크 (Nasdaq: SPRC) 간의 협력에서 비롯된 것으로, 팔미토일에탄올아민(PEA)을 포함한 N-아실에탄올아민 계열과 정신약물 화합물을 결합하는 데 중점을 두고 있습니다. 이 회사는 이 협력과 관련하여 여러 관할권에서 13건의 특허를 제출하여 폭식 행동 치료를 위한 정신약물 치료의 지적 재산 포트폴리오를 강화하고 있습니다.
Clearmind Medicine (Nasdaq: CMND) a annoncé la publication d'une demande de brevet européen pour sa thérapie combinée utilisant MEAI et N-Acylethanolamines. Cette thérapie cible divers comportements de frénésie, y compris l'alcool, la consommation alimentaire, le tabac, le shopping et la conduite sexuelle.
Le brevet découle de la collaboration entre Clearmind et SciSparc (Nasdaq: SPRC), se concentrant sur la combinaison de composés psychédéliques avec la famille des N-Acylethanolamines, y compris la Palmitoiléthanolamine (PEA). L'entreprise a déposé 13 brevets dans plusieurs juridictions liés à cette collaboration, renforçant ainsi son portefeuille de propriété intellectuelle dans les thérapies psychédéliques pour le traitement des comportements de frénésie.
Clearmind Medicine (Nasdaq: CMND) gab die Veröffentlichung einer europäischen Patentanmeldung für seine Kombinationstherapie mit MEAI und N-Acylethanolaminen bekannt. Die Therapie richtet sich gegen verschiedene Binge-Verhaltensweisen, einschließlich Alkohol, Essen, Tabak, Einkauf und sexuellem Verhalten.
Das Patent stammt aus der Zusammenarbeit von Clearmind mit SciSparc (Nasdaq: SPRC), die sich auf die Kombination von psychedelischen Verbindungen mit der Familie der N-Acylethanolamine, einschließlich Palmitoylethanolamid (PEA), konzentriert. Das Unternehmen hat 13 Patente in mehreren Rechtsordnungen eingereicht, die sich auf diese Zusammenarbeit beziehen, und stärkt damit sein geistiges Eigentumsportfolio im Bereich psychedelischer Therapien zur Behandlung von Binge-Verhalten.
- Publication of European patent application strengthens IP portfolio
- Established collaboration with SciSparc for combination therapy development
- Portfolio of 13 patents filed across multiple jurisdictions
- None.
Insights
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
The patent application refers to Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “To date, we have filed 13 patents in the US and in several other global jurisdictions related to our collaboration with SciSparc. As acceptance of psychedelic therapies continues to grow within the medical community, building a robust intellectual property portfolio establishes Clearmind as a pioneer and leader in the next generation of treatments for binge behavior.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses acceptance of psychedelic therapies continuing to grow within the medical community and how building a robust intellectual property portfolio establishes Clearmind as a pioneer and leader in the next generation of treatments for binge behavior. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new European patent application from Clearmind Medicine (CMND) for?
How many patents has Clearmind Medicine (CMND) filed related to their SciSparc collaboration?
What is the specific focus of Clearmind Medicine's (CMND) collaboration with SciSparc?
What conditions does Clearmind Medicine's (CMND) new patent-pending therapy target?
